Literature DB >> 19377353

The power of "principles" in a national pharmaceuticals strategy.

Catherine S Macpherson1, Nuala P Kenny.   

Abstract

The role of principles in shaping the development of public policy has garnered increasing attention. The authors explore the role of underlying principles in the development of a Canadian National Pharmaceuticals Strategy (NPS), an area in which practical policy development has been disappointing. In analyzing proposed principles for a NPS identified in government documents and by a set of major stakeholder coalitions, they find broad agreement on principles underlying a NPS, particularly regarding equity, accessibility, safety and effectiveness. However, the identification of principles for a NPS has not motivated practical policy progress in this crucial area. Some reasons for this failure are rooted in the current state of ethics and principles in health policy and some in the value-laden, interest-dominated nature of pharmaceutical policy itself.
Copyright © 2009 Longwoods Publishing.

Entities:  

Year:  2009        PMID: 19377353      PMCID: PMC2653701     

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  12 in total

1.  Key concepts in health care priority setting.

Authors:  Rogeer Hoedemaekers; Wim Dekkers
Journal:  Health Care Anal       Date:  2003-12

2.  The policy analysis of 'values talk': lessons from Canadian health reform.

Authors:  Mita Giacomini; Jeremiah Hurley; Irving Gold; Patricia Smith; Julia Abelson
Journal:  Health Policy       Date:  2004-01       Impact factor: 2.980

Review 3.  Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence.

Authors:  Joel Lexchin; Paul Grootendorst
Journal:  Int J Health Serv       Date:  2004       Impact factor: 1.663

4.  Wanted: a new ethics field for health policy analysis.

Authors:  Nuala Kenny; Mita Giacomini
Journal:  Health Care Anal       Date:  2005-12

Review 5.  Moving from opacity to transparency in pharmaceutical policy.

Authors:  Irfan Dhalla; Andreas Laupacis
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

Review 6.  Optimizing the use of prescription drugs in Canada through the Common Drug Review.

Authors:  Mike Tierney; Braden Manns
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

7.  Ethics frameworks in Canadian health policies: foundation, scaffolding, or window dressing?

Authors:  Mita Giacomini; Nuala Kenny; Deirdre DeJean
Journal:  Health Policy       Date:  2008-06-20       Impact factor: 2.980

8.  When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions.

Authors:  Aslam H Anis; Daphne P Guh; Diane Lacaille; Carlo A Marra; Amir A Rashidi; Xin Li; John M Esdaile
Journal:  CMAJ       Date:  2005-11-22       Impact factor: 8.262

9.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons.

Authors:  R Tamblyn; R Laprise; J A Hanley; M Abrahamowicz; S Scott; N Mayo; J Hurley; R Grad; E Latimer; R Perreault; P McLeod; A Huang; P Larochelle; L Mallet
Journal:  JAMA       Date:  2001 Jan 24-31       Impact factor: 56.272

10.  The articulation of values and principles involved in health care reform.

Authors:  N Daniels
Journal:  J Med Philos       Date:  1994-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.